Long-term outcome of ABO-incompatible living-donor liver transplantation: A single-center experience

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 16, Issue 4, 2009, Pages 468-472

  Kawagishi, Naoki ^a   Takeda, Ikuo ^a   Miyagi, Shigehito ^a   Satoh, Kazushige ^a   Akamatsu, Yorihiro ^a   Sekiguchi, Satoshi ^a   Satomi, Susumu ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ABO incompatible; Apheresis; Living donor liver transplantation; Long term; Rituximab

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CD19 ANTIGEN; CYCLOSPORIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT REJECTION; ADULT; ANTIBODY TITER; APHERESIS; ARTICLE; BILE DUCT OBSTRUCTION; BLOOD GROUP ABO INCOMPATIBILITY; CHILD; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INFANT; LIVER FAILURE; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MALE; OUTCOME ASSESSMENT; PERIPHERAL LYMPHOCYTE; PORTAL VEIN OBSTRUCTION; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRESCHOOL CHILD; SCHOOL CHILD; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT OUTCOME;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BILIARY ATRESIA; BLOOD COMPONENT REMOVAL; BLOOD GROUP INCOMPATIBILITY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 67650527333     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00534-009-0074-x     Document Type: Article

References (17)

1. Egawa H, Oike F, Buhler L, Shapiro AM, Minamiguchi S, Haga H, et al. Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation. 2004;77:403-11.
2. Kozaki K, Egawa H, Kasahara M, Oike F, Yoshizawa A, Fukatsu A, et al. Therapeutic strategy and the role of apheresis therapy for ABO incompatible living donor liver transplantation. Ther Apher Dial. 2005;9:285-91.
3. Kawagishi N, Satomi S. ABO-incompatible living donor liver transplantation: New insights into clinical relevance. Transplantation. 2008;85:1523-5.
4. Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S, Kadomura T, et al. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation. 2002;73:1959-61.
5. Hanto DW, Fecteau AH, Alonso MH, Valente JF, Whiting JF. ABO-incompatible liver transplantation with no immunological graft losses using total plasma exchange, splenectomy, and quadruple immunosuppression: Evidence for accommodation. Liver Transpl. 2003;9:22-30.
6. Usuda M, Fujimori K, Koyamada N, Fukumori T, Sekiguchi S, Kawagishi N, et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation. 2005;79:12-6.
7. The Japanese Liver Transplantation Society. Liver transplantation in Japan: Registry by the Japanese Liver Transplantation Society. Isyoku. 2006;41:599-608. (in Japanese with English abstract).
8. Toso C, Al-Qahtani M, Alsaif FA, Bigam DL, Meeberg GA, Shapiro AM, et al. ABO-incompatible liver transplantation for critically ill adult patients. Transpl Int. 2007;20:675-81.
9. Pratschke J, Tullius SG. Promising recent data on ABO incompatible liver transplantation: Restrictions may apply. Transpl Int. 2007;20:647-8.
10. Kawagishi N, Takeda I, Miyagi S, Satoh K, Akamatsu Y, Sekiguchi S, et al. Management of anti-allogeneic antibody elimination by apheresis in living donor liver transplantation. Ther Apher Dial. 2007;11:319-24.
11. Mor E, Skerrett D, Manzarbeita C, Sheiner PA, Schwartz ME, Emre S, et al. Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients. Transplantation. 1995;59:986-90.
12. Heffron T, Welch D, Pillen T, Asolati M, Smallwood G, Hagedorn P, et al. Successful ABO-incompatible pediatric liver transplantation utilizing standard immunosuppression with selective postoperative plasmapheresis. Liver Transpl. 2006;12:972-8.
13. Takahashi K. Recent findings in ABO-incompatible kidney transplantation: classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodation. Clin Exp Nephrol. 2007;11:128-41.
14. Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. safety, pharmacodynamics, and pharmacokinetics. Transplantation. 2004;77:542-8.
15. Monteiro I, McLoughlin L, Fisher A, De la Torre AN, Konery B. Rituximab with plasmapheresis and splenectomy in ABO-incompatible liver transplantation. Transplantation. 2003;76:1648-9.
16. Egawa H, Ohmori K, Haga H, Tsuji H, Yurugi K, Miyagawa-Hayashino A, et al. B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation. Liver Transpl. 2007;13:579-88.
17. Kawagishi N, Satoh K, Enomoto Y, Akamatsu Y, Sekiguchi S, Fukumori T, et al. New strategy for ABO-incompatible living donor liver transplantation with anti-CD20 antibody (rituximab) and plasma exchange. Transplant Proc. 2005;37:1205-6.